Pharmaceuticals - Indonesia

  • Indonesia
  • The Pharmaceuticals market in Indonesia is estimated to achieve a revenue of US$3.76bn by 2024.
  • Among the various markets, Oncology Drugs is projected to be the largest with a market volume of US$0.56bn in 2024.
  • It is expected that the market will experience a steady annual growth rate of 3.98% from 2024 to 2029 (CAGR 2024-2029), resulting in a market volume of US$4.57bn by 2029.
  • In terms of global comparison, United States is anticipated to generate the highest revenue, amounting to US$630.30bn in 2024.
  • Indonesia's pharmaceutical market is experiencing a surge in demand for traditional herbal remedies.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

Indonesia, the world's fourth most populous country, is home to a rapidly developing pharmaceutical market.

Customer preferences:
Indonesian consumers have become increasingly health-conscious in recent years, leading to a growing demand for pharmaceutical products. The country's large and growing middle class is also driving demand for higher-quality healthcare, including pharmaceuticals. As a result, there is a growing demand for both branded and generic drugs.

Trends in the market:
The Indonesian pharmaceutical market has been growing at a steady pace in recent years, driven by a number of factors. One key trend is the increased availability of healthcare services, particularly in rural areas. This has led to a growing demand for pharmaceuticals as more people have access to healthcare.Another trend in the Indonesian pharmaceutical market is the increasing use of e-commerce platforms to purchase drugs. This has made it easier for consumers to access pharmaceutical products, particularly in areas where traditional brick-and-mortar pharmacies are scarce.

Local special circumstances:
Indonesia has a large and highly fragmented pharmaceutical market, with a large number of domestic and international players. This has led to intense competition in the market, with companies vying for market share through aggressive marketing and pricing strategies.The Indonesian government has also been taking steps to increase access to healthcare and pharmaceutical products. For example, the government has implemented a national health insurance program that covers a significant portion of the population. This has helped to increase demand for pharmaceuticals, particularly among lower-income consumers.

Underlying macroeconomic factors:
The Indonesian pharmaceutical market is benefiting from a number of underlying macroeconomic factors. These include a growing middle class, increasing urbanization, and a relatively stable political environment. Additionally, the government has been investing heavily in infrastructure, which has helped to improve access to healthcare services and pharmaceutical products.Overall, the Indonesian pharmaceutical market is poised for continued growth in the coming years. As the country's middle class continues to expand and demand for healthcare services increases, the market for pharmaceutical products is likely to continue to grow. Additionally, the government's focus on improving access to healthcare and pharmaceutical products is likely to provide further support for the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Next generation therapy
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)